Medivation (MDVN): Anemic Growth from Xtandi - Jefferies
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Jefferies analyst, Biren Amin, reiterated his Hold rating on shares of Medivation (NASDAQ: MDVN) after management disclosed a 3% q/q growth due to underlying demand for Xtandi. in Q2. This anemic number is concerning especially when combined with worse gtn and inventory stocking.
One positive trend that could continue is increased duration of Xtandi currently ~9 months and could increase if STRIVE/TERRAIN data are included in the label by the Oct 22 PDUFA. Therefore, the analyst felt comfortable raising his price target to $60 from $56.
Shares of Medivation closed at $63.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
- Imperial Capital Raises Price Target on Spirit Airlines (SAVE); Cuts 4Q Estimates
- Leerink Partners Cuts Price Target on Cynosure (CYNO) Following Solid 3Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesJefferies & Co, PDUFA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!